Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Polyvalent Vaccines and Methods for Making Them, 28791 [2024-08361]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 77 / Friday, April 19, 2024 / Notices
Dated: April 15, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–08286 Filed 4–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License, Inter-Institutional AgreementInstitution Lead: Polyvalent Vaccines
and Methods for Making Them
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, on behalf of the
Centers for Disease Control and
Prevention, Department of Health and
Human Services, is contemplating the
grant of an exclusive, sublicensable
patent license to University Health
Network, located in Toronto, Canada, its
rights to the technologies and the patent
applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the Technology Transfer
and Intellectual Property Office,
National Institute of Allergy and
Infectious Diseases on or before May 6,
2024 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Ann Marie Flammang Ph.D.,
Senior Technology Transfer Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Suite 2G,
MSC9804, Rockville, MD 20852–9804,
phone number 301–761–6682, or
annmarie.flammang@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: United States
Provisional Patent Application Number
63/278,467, filed November 11, 2021,
entitled ‘‘Polyvalent Vaccines and
Methods for Making Them’’ (HHS
Reference No. E–091–2024–0–US–01),
and Patent Cooperation Treaty Patent
Application Number PCT/CA2022/
051680, filed November 14, 2022,
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
02:06 Apr 19, 2024
Jkt 262001
entitled ‘‘Polyvalent Vaccines and
Methods for Making Them’’ (HHS
Reference No. E–091–2024–0–PC–01).
All patent rights in these inventions
have been assigned to University Health
Network, University of Liverpool, The
Governing Council of the University of
Toronto, and Centers for Disease Control
and Prevention.
The prospective patent license will be
for the purpose of consolidating the
patent rights to University Health
Network, the co-owners of said rights,
for commercialization. Consolidation of
these co-owned rights is intended to
expedite development of the
technology, consistent with the goals of
the Bayh-Dole Act codified as 35 U.S.C.
200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by University
Health Network will be subject to the
provisions of 37 CFR part 404.
The technology is a strategy to
overcome the challenge of virus
heterogeneity against hepatitis C virus
(HCV). Using a model of hypervariable
region 1 (HRV1) genetic variability and
observed discrete, genotypeindependent clusters, sequences were
selected to synthesize peptides for
vaccination. The pentavalent mixture
resulted in an antibody response that
was more broadly neutralizing than
each individual variant or pooled sera,
indicating a synergistic interaction
among immune responses to related, but
distinct, HVR1 variants. These findings
open a new path for the development of
an HCV vaccine using sequence
complementary variants of genetically
divergent HVR1 antigenic epitopes. A
method was developed for producing a
multivariant vaccine comprised of a
plurality of peptides or the nucleic acids
encoding them.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Insitute of Allergy and Infectious
Diseases receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
28791
confidentially, and may be made
publicly available.
Complete license applications
submitted in response to this Notice
will be presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: April 15, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–08361 Filed 4–18–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR 6453–N–01]
Announcement of Tenant Protection
Voucher Funding Awards for Fiscal
Year 2023 for the Housing Choice
Voucher Program
Office of the Assistant
Secretary for Public and Indian
Housing, HUD.
ACTION: Notice of fiscal year 2023
awards.
AGENCY:
In accordance with the
Department of Housing and Urban
Development Reform Act of 1989, this
document notifies the public of Tenant
Protection Voucher (TPV) funding
awards for fiscal year (FY) 2023 to
public housing agencies (PHAs) under
the Section 8 Housing Choice Voucher
Program (HCVP). The purpose of this
notice is to publish the names,
addresses of awardees, and the amount
of their non-competitive funding awards
for assisting households affected by
housing conversion actions, public
housing relocations and replacements,
and moderate rehabilitation
replacements. This notice also includes
a link to the TPV awards issued since
FY 2020, which can be sorted by PHAs,
project name and identification number,
by category of TPVs such as Multifamily
or Public Housing, and by state and by
HUD regions.
FOR FURTHER INFORMATION CONTACT:
Danielle L. Bastarache, Deputy Assistant
Secretary, Office of Public Housing and
Voucher Programs, Office of Public and
Indian Housing, Department of Housing
and Urban Development, 451 Seventh
Street SW, Room 4204, Washington, DC
20410–5000, telephone (202) 402–1380.
HUD welcomes and is prepared to
receive calls from individuals who are
SUMMARY:
E:\FR\FM\19APN1.SGM
19APN1
]]>Agencies
[Federal Register Volume 89, Number 77 (Friday, April 19, 2024)]
[Notices]
[Page 28791]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08361]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License, Inter-Institutional
Agreement-Institution Lead: Polyvalent Vaccines and Methods for Making
Them
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, on behalf of the Centers for Disease Control and
Prevention, Department of Health and Human Services, is contemplating
the grant of an exclusive, sublicensable patent license to University
Health Network, located in Toronto, Canada, its rights to the
technologies and the patent applications listed in the SUPPLEMENTARY
INFORMATION section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases on or
before May 6, 2024 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Ann Marie Flammang Ph.D., Senior Technology
Transfer Patent Specialist, Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone
number 301-761-6682, or [email protected].
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: United States
Provisional Patent Application Number 63/278,467, filed November 11,
2021, entitled ``Polyvalent Vaccines and Methods for Making Them'' (HHS
Reference No. E-091-2024-0-US-01), and Patent Cooperation Treaty Patent
Application Number PCT/CA2022/051680, filed November 14, 2022, entitled
``Polyvalent Vaccines and Methods for Making Them'' (HHS Reference No.
E-091-2024-0-PC-01). All patent rights in these inventions have been
assigned to University Health Network, University of Liverpool, The
Governing Council of the University of Toronto, and Centers for Disease
Control and Prevention.
The prospective patent license will be for the purpose of
consolidating the patent rights to University Health Network, the co-
owners of said rights, for commercialization. Consolidation of these
co-owned rights is intended to expedite development of the technology,
consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C.
200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
University Health Network will be subject to the provisions of 37 CFR
part 404.
The technology is a strategy to overcome the challenge of virus
heterogeneity against hepatitis C virus (HCV). Using a model of
hypervariable region 1 (HRV1) genetic variability and observed
discrete, genotype-independent clusters, sequences were selected to
synthesize peptides for vaccination. The pentavalent mixture resulted
in an antibody response that was more broadly neutralizing than each
individual variant or pooled sera, indicating a synergistic interaction
among immune responses to related, but distinct, HVR1 variants. These
findings open a new path for the development of an HCV vaccine using
sequence complementary variants of genetically divergent HVR1 antigenic
epitopes. A method was developed for producing a multivariant vaccine
comprised of a plurality of peptides or the nucleic acids encoding
them.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Insitute of Allergy and Infectious Diseases receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
Complete license applications submitted in response to this Notice
will be presumed to contain business confidential information and any
release of information in these license applications will be made only
as required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 15, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-08361 Filed 4-18-24; 8:45 am]
BILLING CODE 4140-01-P
